QIAGEN

There’s a new collaboration in the Parkinson’s disease development space, Cardiff Oncology kicks off a mid-phase study in colorectal cancer and Ocugen published a new review of COVAXIN.

The two companies will collaborate to market Verogen’s forensically validated NGS workflows alongside QIAGEN’s full range of forensic-grade chemistries and sample prep automation.

The increase reflects the positive financial impact COVID-19 has had on the European diagnostic company’s bottom line.

As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization last week. Here’s a biopharma industry overview as of late March 16.

Qiagen manufactures diagnostic tests for a variety of diseases including cancer and, currently, the coronavirus that causes COVID-19.

Luminostics, Inc., to receive $10,000 cash prize and recognition from the rapid point-of-care diagnostics industry

DCN Dx and Qiagen Lake Constance are pleased to announce five finalists for its second Rapid Testing Innovation Award.

Companies strengthen their leadership teams and boards of directors with these appointments.

The collaboration will focus on Inovio’s VGX-3100, which stimulates a specific immune response to HPV-16 and HPV-18, targeting the infection and causing destruction of precancerous cells.